Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Daily News

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

L.A. McKeown

July 02, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News ACC 2024

ADHD Meds Linked to Cardiomyopathy in Young Adults

Todd Neale

April 01, 2024

News Daily News

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

Todd Neale

January 11, 2024

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

News Daily News

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Michael O'Riordan

July 11, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Michael O'Riordan

August 14, 2020

News Features

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Shelley Wood

July 20, 2020

News Daily News

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

L.A. McKeown

March 25, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

January 2025 Dispatch for the CV Team

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

September 2024 Dispatch for the CV Team

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

ADHD Meds Linked to Cardiomyopathy in Young Adults

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Dapagliflozin Boosts Health Status Across LVEF Range

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Could Statins Curb Fatal or Severe COVID-19? Some Clues

COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content